Access to biologics for rheumatoid arthritis varies widely in Europe
This article was originally published in Scrip
Executive Summary
There are large inequalities in access to innovative biologic rheumatoid arthritis (RA) treatments across Europe, says a new study published in the European Journal of Health Economics. Variations in drug affordability, standardised prices and health technology assessments all take their toll on uptake to varying degrees.